Seres Therapeutics Inc
MCRB
Get informed when a big investor buys or sells
+ FollowMarket Cap$49.48M
Close$
$-3.58
162.5% downside
Current Fair Value
162.5% downsideOvervalued by 162.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $49.48 Million |
|---|---|
| Enterprise Value | $90.53 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.64 |
| Beta | 0.21 |
| Outstanding Shares | 9,644,704 |
Return
| Return on Equity | -65.05% |
|---|---|
| Return on Assets | -22.11% |
| Return on Invested Capital | -103.99% |
Valuation & Multiples
| P/E Ratio | -2.11 |
|---|---|
| PEG | 1.72 |
| Price to Sales | - |
| Price to Book Ratio | 1.91 |
| Enterprise Value to Revenue | 48.08 |
| Enterprise Value to EBIT | -1.07 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.63 |
| Debt to Equity | 1.64 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-2.18
Average shareholder expectationRevenue Estimate
$179,000
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.00
Average shareholder expectationRevenue Estimate
$6.35 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.1940▲ 146.23% |
|---|---|
| Total Calls | 56,700▼ 67.34% |
| Total Puts | 124,400▼ 2.07% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.07%▼ 3.49% |
|---|---|
| Total Invested | $20.46M▼ 43.75% |
| Investors Holding | 36▼ 4.00% |
ESG Score
No data
About Seres Therapeutics Inc
CEO: Eric Shaff